Here are a couple of brief analogies for Jazz Pharmaceuticals:

• Biogen for sleep disorders and oncology.

• Vertex Pharmaceuticals for specialized neuroscience and cancer treatments.

• Xyrem: An oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
• Sunosi: Treats excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea.
• Erwinaze: Used to treat acute lymphoblastic leukemia.
• Defitelio: Treats hepatic veno-occlusive disease in adult and pediatric patients.
• Vyxeos liposome for injection: Treats adults with newly-diagnosed therapy-related acute myeloid leukemia.
• Zepzelca: Treats adult patients with metastatic small cell lung cancer.

Jazz Pharmaceuticals (JAZZ) is a biopharmaceutical company that develops and commercializes pharmaceutical products. As such, the company sells its products primarily to other companies within the healthcare supply chain rather than directly to individual consumers. The provided background information does not list the names of specific major customer companies, but its major customers generally fall into the following categories:

• Pharmaceutical Wholesalers and Distributors: These companies purchase pharmaceutical products from manufacturers like Jazz Pharmaceuticals and then distribute them to various healthcare providers, including pharmacies and hospitals.
• Hospitals and Healthcare Systems: These institutions purchase medications for in-patient use, clinics, and sometimes for dispensing to out-patients.
• Retail Pharmacies: These establishments acquire drugs (often through wholesalers) to dispense to individual patients based on prescriptions.

Renée Galá President and Chief Executive Officer

Renée Galá became President and Chief Executive Officer of Jazz Pharmaceuticals, effective August 11, 2025. She previously served as the company's President and Chief Operating Officer from October 2023, and as Executive Vice President and Chief Financial Officer from March 2020. Prior to joining Jazz, Ms. Galá was Chief Financial Officer of GRAIL Inc., a healthcare company focused on early cancer detection. From 2014 to 2019, she served as Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc., following its spin-out from Theravance, Inc. (now Innoviva, Inc.), where she had held various finance roles since 2006. Earlier in her career, Ms. Galá held roles in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company, and spent seven years in the energy industry in corporate finance, project finance, and mergers and acquisitions. Ms. Galá currently serves on the board of Dexcom and previously served on the boards of Gossamer Bio, Corcept Therapeutics, and Gyroscope Therapeutics, which was acquired by Novartis.

Philip L. Johnson Executive Vice President and Chief Financial Officer

Philip L. Johnson was appointed Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals, effective March 1, 2024. Mr. Johnson brings over 35 years of financial experience, most recently spending nearly three decades at Eli Lilly and Company. At Eli Lilly, he served as Group Vice President of Finance, leading the company's treasury and investor relations operations. He held various senior leadership positions in finance globally, gaining experience in Japan, Latin America, Spain, Italy, and the U.S. Before his career at Eli Lilly, Mr. Johnson worked as a management consultant for McKinsey & Co. and with investment banks in Milan, Italy, and Chicago, Illinois. He also serves on several boards and committees, including the Indiana Chamber of Commerce, Indianapolis Urban League, Equity 1821, Lynx Capital, and AMR Action Fund.

Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research and Development, Chief Medical Officer

Dr. Robert Iannone has served as Jazz Pharmaceuticals' Executive Vice President and Global Head of Research and Development since May 2019. He is responsible for overseeing all aspects of preclinical research, clinical development, clinical operations, and regulatory affairs. Dr. Iannone has over 18 years of experience in clinical drug development, working across various therapeutic areas and development phases. Prior to joining Jazz, he worked on immuno-oncology programs at Merck, AstraZeneca, and Immunomedics. From April 2018 to May 2019, Dr. Iannone was the head of research and development and chief medical officer of Immunomedics, Inc.

Liz Henderson Senior Vice President, Technical Operations

Liz Henderson was appointed Senior Vice President, Technical Operations at Jazz Pharmaceuticals in August 2023. She possesses extensive experience in commercial leadership roles at both regional and global levels, with expertise in technical operations, global manufacturing, and supply chain management.

Robert Mackey Senior Vice President, Global Product Commercialization

Robert Mackey is the Senior Vice President of Global Product Commercialization at Jazz Pharmaceuticals. Before joining Jazz, Mr. Mackey held various commercial and therapeutic area leadership positions at both large and emerging biopharmaceutical companies. His previous roles include Vice President of Commercial Development at Portola Pharmaceuticals (2011-2013), Vice President of Endocrine Marketing at Ipsen / Tercica (2008-2011), and leading portfolio and launch planning for Xarelto at Johnson & Johnson (2006-2008). He also spent several years at Genentech (1997-2004) focusing on product launches, brand leadership, and managed care.

The key risks to Jazz Pharmaceuticals' business revolve around its reliance on its established product portfolio, particularly within its neuroscience segment, and the challenges inherent in the highly regulated biopharmaceutical industry.

1. Loss of Exclusivity for Key Oxybate Products: A significant portion of Jazz Pharmaceuticals' revenue has historically come from its oxybate franchise, including Xyrem and Xywav. The anticipated entry of generic versions of Xyrem by 2026 poses a notable risk to the company's financial outlook. While Xywav, a low-sodium alternative, has been strategically introduced and has seen significant revenue growth, its last outstanding exclusivity is expected to expire in 2028, with the earliest generic entry estimated for August 12, 2028, based on patents and regulatory protections. The company's over-reliance on Xywav and Epidiolex presents a risk, as payer pushback or eventual generic challenges could erode exclusivity.
2. Intense Competition in Key Therapeutic Areas: Jazz Pharmaceuticals operates in an extremely competitive and dynamic market, particularly in sleep disorders and oncology. Increased competition is on the horizon in the narcolepsy market, including from alternative treatments and new branded competitors such as Avadel's Lumryz, which poses a substantial risk to revenue for Jazz's oxybate franchise. This intense competition, coupled with potential pricing pressures, could impact the company's market share and profitability across its neuroscience and oncology portfolios.
3. Regulatory and Litigation Challenges, and Pipeline Development Risk: Operating in a highly regulated industry, Jazz Pharmaceuticals is exposed to significant ongoing regulatory obligations and oversight, with "Legal & Regulatory" identified as a top risk category. This includes risks from ongoing patent litigation that could affect market exclusivity for key products, as well as regulatory scrutiny over drug pricing and antitrust claims. Furthermore, the company's long-term growth is dependent on the successful identification, development, and regulatory approval of new product candidates in its pipeline. The process of obtaining and maintaining FDA approvals for new drugs is lengthy and uncertain, with no guarantee of success despite substantial investments in research and development. Failures in clinical trials or delays in regulatory approvals for pipeline assets could limit future revenue streams.

Here are the addressable markets for Jazz Pharmaceuticals' main products:

• Xyrem (narcolepsy with cataplexy and excessive daytime sleepiness (EDS)) and Xywav (EDS and cataplexy with narcolepsy and idiopathic hypersomnia):

  The market size for specific medications for narcolepsy and idiopathic hypersomnia is not distinctly segmented in the available information. However, for context, the broader global Obstructive Sleep Apnea (OSA) treatment market (therapies), which includes treatments for EDS, was nearly USD 359 million in the 7MM (7 major markets) in 2023. The U.S. market for Obstructive Sleep Apnea treatment accounted for approximately USD 247 million in 2023.

• Sunosi (EDS in patients with narcolepsy and obstructive sleep apnea):

  The global Obstructive Sleep Apnea (OSA) treatment market (therapies), which addresses EDS, was nearly USD 359 million in the 7MM in 2023. The U.S. market for Obstructive Sleep Apnea treatment was approximately USD 247 million in 2023.

• Erwinaze and JZP458 (Acute Lymphoblastic Leukemia - ALL):

  The global Acute Lymphoblastic Leukemia (ALL) therapeutics market was valued at approximately USD 3.745 billion in 2024. North America held a 38% market share of the global ALL therapeutics market in 2024. The U.S. market for ALL therapeutics is estimated to be approximately USD 1.26 billion in 2024 (calculated based on 38% North American share and U.S. dominating North America with 89.3% share).

• Defitelio (hepatic veno-occlusive disease):

  The global Veno-Occlusive Hepatic Disease therapeutics market was valued at USD 262.87 million in 2024. The U.S. Veno-Occlusive Hepatic Disease therapeutics market is estimated to be valued at USD 104.8 million in 2025.

• Vyxeos (newly-diagnosed therapy-related acute myeloid leukemia - AML):

  The global acute myeloid leukemia (AML) treatment market was estimated at USD 3.47 billion in 2024. North America dominated the global market with a share of 37.6% in 2024, and the U.S. market dominated North America with a 90.9% share in 2024. The U.S. AML treatment market is estimated to be approximately USD 1.18 billion in 2024.

• Zepzelca (metastatic small cell lung cancer):

  null

• JZP385 (essential tremor):

  The global essential tremor treatment market was valued at USD 151.25 million in 2024. North America held the largest share of the market, accounting for 41% in 2024. The U.S. market for essential tremor treatment is estimated to be approximately USD 62.01 million in 2024.

• JZP150 (post-traumatic stress disorder):

  null

Here are 3-5 expected drivers of future revenue growth for Jazz Pharmaceuticals (JAZZ) over the next 2-3 years:

1. Continued Growth of Xywav: Jazz Pharmaceuticals anticipates sustained revenue growth from Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of narcolepsy and idiopathic hypersomnia (IH). Xywav is positioned as the preferred low-sodium oxybate, serving as the leading branded treatment for narcolepsy and the sole FDA-approved therapy for IH. The company expects continued strong new patient additions and benefits from patent protection extending into the 2030s. Xywav achieved $1.7 billion in revenue in 2025, representing a 12% year-over-year increase, and is projected to reach approximately $2 billion in annual revenue.
2. Expansion of Epidiolex/Epidyolex: Epidiolex (cannabidiol), which achieved blockbuster status with $1.1 billion in sales in 2025, is a significant growth driver. Its growth is fueled by sustained prescription demand, increasing utilization across patient populations, including adults, and ongoing global launches. Epidiolex benefits from patent protections that extend into the late 2030s, mitigating risks from generic competition. The drug consistently contributes a substantial portion of the company's total revenue.
3. Zepzelca Expansion into First-Line Small Cell Lung Cancer (SCLC): Zepzelca (lurbinectedin) is expected to drive future revenue growth through its expanded approval for first-line (1L) maintenance treatment of extensive-stage SCLC (ES-SCLC) in combination with atezolizumab. This expanded indication significantly increases the addressable patient population and duration of therapy, with the potential for Zepzelca to reach blockbuster status in the coming years. While sales in its initial second-line indication have faced competition, the move to a front-line setting unlocks a larger market opportunity.
4. Launch and Indication Expansion of Zanidatamab: Zanidatamab is a key oncology pipeline asset anticipated to be a significant revenue driver. The company expects to complete its supplemental biologics license application (sBLA) submission in the first quarter of 2026 for zanidatamab in HER2-positive first-line gastroesophageal adenocarcinoma (GEA), with a potential launch in the second half of 2026. Positive Phase 3 data for zanidatamab in HER2+ GEA supports its potential to become the HER2-targeted therapy of choice, and ongoing clinical trials for HER2+ breast cancer and other indications present further growth opportunities.

Share Repurchases

• In July 2024, Jazz Pharmaceuticals' Board of Directors authorized a new share repurchase program, allowing the company to repurchase its ordinary shares for up to an aggregate purchase price of $500 million, with no expiration date.
• During the second quarter of 2024, the company resumed repurchases on the open market, purchasing approximately $161 million of its ordinary shares under a previously authorized program.
• Concurrently with a private offering of exchangeable senior notes in September 2024, Jazz Pharmaceuticals repurchased approximately $150 million of its ordinary shares.

Share Issuance

• In September 2024, Jazz Pharmaceuticals announced a private offering of $850 million aggregate principal amount of exchangeable senior notes due 2030, with the potential for an additional $150 million. The company's exchange obligation for these notes can be settled in cash, ordinary shares, or a combination thereof.
• Jazz Pharmaceuticals also offers an employee stock purchase plan, allowing eligible employees to acquire ordinary shares at a 15% discount through payroll deductions.

Outbound Investments

• In January 2021, Jazz Pharmaceuticals acquired GW Pharmaceuticals for US$7.2 billion, significantly expanding its neuroscience portfolio with the addition of medications like Epidiolex.
• The company completed the acquisition of Chimerix for approximately $935 million in cash in April 2025, which bolstered its oncology pipeline with dordaviprone.
• In February 2024, Jazz Pharmaceuticals entered into a licensing agreement with Redx Pharma plc for a KRAS inhibitor program, with the deal potentially valued at up to $880 million.

Capital Expenditures

• Jazz Pharmaceuticals' capital expenditures have been relatively low over the past few years, reflecting the company's strategy of relying on third-party manufacturers and outsourcing all of its production.
• Capital expenditures were reported as $36 million in 2025, $9.69 million in 2024, and $29 million in 2023.
• The company focuses its strategic investments on expanding its existing marketed products, advancing its R&D pipeline, and exploring new rare disease areas and potential acquisitions.